DBV filed its French half-year report with the AMF as it reported June 30 cash of $174.9 million and said funding should support operations into the third quarter of 2027.
DBV Technologies reported second-quarter and half-year 2026 results and said it filed its 2026 Half-Year Report with the AMF, France’s financial markets regulator. The company continues preparing a biologics license application, or BLA, for the VIASKIN Peanut Patch in children aged 4 through 7 years and now expects to submit it in the third quarter of 2026 after discussions with the FDA, which DBV said has not requested additional data and has provided feedback on the organization, mapping and formatting of existing CMC and biostatistical data sets. DBV posted a net loss of $98.0 million for the first half and $50.4 million for the second quarter, with cash and cash equivalents of $174.9 million at June 30, 2026; management said that, based on current plans and assumptions, the company is funded into the third quarter of 2027.